Akari Therapeutics PLC
AKTX1.025USD
+0.015+1.49%
Market hours （ET）Quotes delayed by 15 min
29.60MMarket Cap
LossP/E TTM
More Details of Akari Therapeutics PLC Company
Akari Therapeutics, Plc is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. The Company is engaged in the development of antibody drug conjugates (ADCs) and advanced therapies for autoimmune and inflammatory diseases, including geographic atrophy (GA). Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The Company is conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). It is conducting a phase III clinical trial in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The Company's pipeline also includes the PH-1 ADC Platform for oncology, PHP-303 program for genetic disease, liver disease and inflammation, specifically for Alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS), including COVID-19.
Company Info
Ticker SymbolAKTX
Company nameAkari Therapeutics PLC
IPO dateJan 31, 2014
CEOMr. Abizer Gaslightwala
Number of employees8
Security typeDepository Receipt
Fiscal year-endJan 31
Address22 Boston Wharf Road
CityBOSTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02210
Phone16463500702
Websitehttps://www.akaritx.com/
Ticker SymbolAKTX
IPO dateJan 31, 2014
CEOMr. Abizer Gaslightwala
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Hoyoung Huh, M.D., Ph.D.
Mr. Hoyoung Huh, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.70M
+23.48%
Dr. Raymond (Ray) Prudo-chlebosz, M.D.
Dr. Raymond (Ray) Prudo-chlebosz, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.46M
+22.20%
Mr. Abizer Gaslightwala
Mr. Abizer Gaslightwala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
241.71K
+66.05%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
44.64K
--
Dr. Torsten Hombeck, Ph.D.
Dr. Torsten Hombeck, Ph.D.
Chief Financial Officer
Chief Financial Officer
638.00
--
Mr. Sandip I Patel, J.D.
Mr. Sandip I Patel, J.D.
Independent Director
Independent Director
--
--
Mr. James Neal
Mr. James Neal
Independent Director
Independent Director
--
--
Dr. Samir R. Patel, M.D.
Dr. Samir R. Patel, M.D.
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Hoyoung Huh, M.D., Ph.D.
Mr. Hoyoung Huh, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.70M
+23.48%
Dr. Raymond (Ray) Prudo-chlebosz, M.D.
Dr. Raymond (Ray) Prudo-chlebosz, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.46M
+22.20%
Mr. Abizer Gaslightwala
Mr. Abizer Gaslightwala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
241.71K
+66.05%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
44.64K
--
Dr. Torsten Hombeck, Ph.D.
Dr. Torsten Hombeck, Ph.D.
Chief Financial Officer
Chief Financial Officer
638.00
--
Mr. Sandip I Patel, J.D.
Mr. Sandip I Patel, J.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Huh (Hoyoung)
14.59%
Patel (Samir Rashmikant)
8.28%
Prudo-Chlebosz (Raymond)
7.64%
Theofilos (Charles Steve)
3.30%
Gaslightwala (Abizer)
0.75%
Other
65.44%
Shareholders
Shareholders
Proportion
Huh (Hoyoung)
14.59%
Patel (Samir Rashmikant)
8.28%
Prudo-Chlebosz (Raymond)
7.64%
Theofilos (Charles Steve)
3.30%
Gaslightwala (Abizer)
0.75%
Other
65.44%
Shareholder Types
Shareholders
Proportion
Individual Investor
34.70%
Hedge Fund
0.51%
Investment Advisor
0.33%
Investment Advisor/Hedge Fund
0.06%
Other
64.40%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
36
11.46M
35.60%
+3.31M
2025Q1
37
11.38M
35.52%
+3.37M
2024Q4
33
9.87M
39.88%
+5.88M
2024Q3
29
4.76M
34.87%
+2.88M
2024Q2
30
4.75M
35.12%
+2.92M
2024Q1
29
1.60M
27.12%
+425.92K
2023Q4
29
1.07M
21.26%
-130.49K
2023Q3
29
1.12M
24.19%
+287.97K
2023Q2
29
1.32M
71.27%
+488.46K
2023Q1
30
1.33M
28.24%
+711.53K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Huh (Hoyoung)
4.70M
14.59%
+892.86K
+23.48%
Mar 06, 2025
Patel (Samir Rashmikant)
2.66M
8.28%
+957.65K
+56.14%
Nov 14, 2024
Prudo-Chlebosz (Raymond)
2.46M
7.64%
+446.43K
+22.20%
Mar 06, 2025
Theofilos (Charles Steve)
1.06M
3.3%
+1.06M
--
May 31, 2024
Gaslightwala (Abizer)
241.71K
0.75%
+96.15K
+66.05%
Jun 24, 2025
Palo Alto Investors LP
146.02K
0.45%
--
--
Mar 31, 2025
Omnia Family Wealth, LLC
87.63K
0.27%
--
--
Mar 31, 2025
Bazemore (Robert B)
44.64K
0.14%
+44.64K
--
Mar 06, 2025
Cerity Partners LLC
23.64K
0.07%
--
--
Mar 31, 2025
Cresset Asset Management, LLC
18.41K
0.06%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 15, 2023
Merger
20<1
Aug 15, 2023
Merger
20<1
Aug 15, 2023
Merger
20<1
Aug 15, 2023
Merger
20<1
Date
Type
Ratio
Aug 15, 2023
Merger
20<1
Aug 15, 2023
Merger
20<1
Aug 15, 2023
Merger
20<1
Aug 15, 2023
Merger
20<1
